The Effects of Antisense AKT2 RNA on the Inhibition of Malignant Glioma Cell Growth in Vitro and in Vivo

Overview

Journal J Neurooncol

Publisher Springer

Date 2006 Jan 13

PMID 16402276

Citations 21

Authors

Peiyu Pu

Chunsheng Kang

Jie Li

Hao Jiang

Jinquan Cheng

Affiliations

Soon will be listed here.

Abstract

The oncogenic role of AKT2 in the development of malignant gliomas was examined by using antisense approach. AKT2 expression was significantly inhibited in rat C6 glioma cells transfected with antisense AKT2 cDNA construct (LXSN-AS-AKT2). In addition, the transfected cells proliferated at a lowered level and apoptosis was induced. For in vivo studies, parental C6 cells and C6 cells transfected with LXSN-AS-AKT2 were implanted stereotactically into the right caudate nucleus of SD rats (control C6 group and transfected group). The rats bearing well-established C6 gliomas were treated with LXSN-AS-AKT2 DNA or LXSN (empty vector)-lipofectamine complexes intratumorally (treated group and control treated group). The mean survival of the rats of control C6 group and treated control group was 17.8+/-0.92 days and 17.5+/-1.10 days, respectively. The mean survival of the rats of transfected and treated group was significantly prolonged. MR images revealed distinct cerebral tumor foci in all of the control rats, whereas four rats in transfected group did not develop tumors and the tumor foci in five rats of treated group were regressed and disappeared. The expression of AKT2, PCNA, MMP2/9, and cyclin D were inhibited in the tumors of rats in transfected and treated groups while GFAP expression was increased. These results suggest that AKT pathway may play an important role in the development and progression of gliomas. Anti-AKT approach will open a new perspective for a targeted molecular therapy of malignant gliomas.

Citing Articles

Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma.

Desgraves J, Valdez M, Chandar J, Gurses M, Henderson L, Castro J Cancers (Basel). 2024; 16(10).

PMID: 38792022 PMC: 11119631. DOI: 10.3390/cancers16101944.

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.

Bader J, Deigendesch N, Misch M, Mann M, Koch A, Meissner F Cell Rep Med. 2022; 4(1):100877.

PMID: 36584682 PMC: 9873829. DOI: 10.1016/j.xcrm.2022.100877.

TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment.

Chen Y, Shih P, Kuo H, Yang S, Lin Y, Chen W Cancer Med. 2020; 9(11):3918-3931.

PMID: 32266797 PMC: 7286473. DOI: 10.1002/cam4.3005.

Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway.

Hakimee H, Hutamekalin P, Tanasawet S, Chonpathompikunlert P, Tipmanee V, Sukketsiri W Asian Pac J Cancer Prev. 2019; 20(12):3539-3545.

PMID: 31870092 PMC: 7173373. DOI: 10.31557/APJCP.2019.20.12.3539.

Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.

Nan Y, Guo L, Song Y, Wang L, Yu K, Huang Q J Cancer Res Clin Oncol. 2017; 143(8):1477-1487.

PMID: 28401302 DOI: 10.1007/s00432-017-2415-5.

References

Shalev N, Wong M, Mills G, Yount G, Stokoe D . Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998; 8(21):1195-8. DOI: 10.1016/s0960-9822(07)00493-9. View

Toda M, Miura M, Asou H, Toya S, Uyemura K . Cell growth suppression of astrocytoma C6 cells by glial fibrillary acidic protein cDNA transfection. J Neurochem. 1994; 63(5):1975-8. DOI: 10.1046/j.1471-4159.1994.63051975.x. View

Sun M, Wang G, Paciga J, Feldman R, Yuan Z, Ma X . AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001; 159(2):431-7. PMC: 1850562. DOI: 10.1016/s0002-9440(10)61714-2. View

Pu P, Liu X, Liu A, Cui J, Zhang Y . Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. J Neurosurg. 2000; 92(1):132-9. DOI: 10.3171/jns.2000.92.1.0132. View

Martin M, Franke T, Stoica G, Chambon P, Katzenellenbogen B, Stoica B . A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology. 2000; 141(12):4503-11. DOI: 10.1210/endo.141.12.7836. View

Uhm J, Dooley N, Villemure J, Yong V . Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci. 1997; 24(1):3-15. DOI: 10.1017/s0317167100021028. View

Pekny M, Eliasson C, Chien C, Kindblom L, Liem R, Hamberger A . GFAP-deficient astrocytes are capable of stellation in vitro when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density. Exp Cell Res. 1998; 239(2):332-43. DOI: 10.1006/excr.1997.3922. View

Sonoda Y, Ozawa T, Aldape K, Deen D, Berger M, Pieper R . Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001; 61(18):6674-8. View

Trojan J, Blossey B, Johnson T, Rudin S, Tykocinski M, Ilan J . Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci U S A. 1992; 89(11):4874-8. PMC: 49190. DOI: 10.1073/pnas.89.11.4874. View

10.

Michell B, Griffiths J, Mitchelhill K, Rodriguez-Crespo I, Tiganis T, Bozinovski S . The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999; 9(15):845-8. DOI: 10.1016/s0960-9822(99)80371-6. View

11.

Bellacosa A, De Feo D, Godwin A, BELL D, Cheng J, Altomare D . Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64(4):280-5. DOI: 10.1002/ijc.2910640412. View

12.

Nakayama H, Ikebe T, Beppu M, Shirasuna K . High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer. 2001; 92(12):3037-44. DOI: 10.1002/1097-0142(20011215)92:12<3037::aid-cncr10171>3.0.co;2-#. View

13.

Schlegel J, Piontek G, Mennel H . Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo. Anticancer Res. 2003; 22(5):2837-40. View

14.

Sandberg-Nordqvist A, Stahlbom P, Reinecke M, Collins V, von Holst H, Sara V . Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res. 1993; 53(11):2475-8. View

15.

Narita Y, Nagane M, Mishima K, Huang H, Furnari F, Cavenee W . Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002; 62(22):6764-9. View

16.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

17.

Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T . AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992; 89(19):9267-71. PMC: 50107. DOI: 10.1073/pnas.89.19.9267. View

18.

Kubiatowski T, Jang T, Lachyankar M, Salmonsen R, Nabi R, Quesenberry P . Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg. 2001; 95(3):480-8. DOI: 10.3171/jns.2001.95.3.0480. View

19.

Cheng J, Ruggeri B, Klein W, Sonoda G, Altomare D, Watson D . Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996; 93(8):3636-41. PMC: 39663. DOI: 10.1073/pnas.93.8.3636. View

20.

Liao Y, Grobholz R, Abel U, Trojan L, Michel M, Angel P . Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer. 2003; 107(4):676-80. DOI: 10.1002/ijc.11471. View